Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia

Keyphrases

• Fusion Protein 100%
• Chronic Myeloid Leukemia 100%
• BCR-ABL1 100%
• Kinase-independent 100%
• ABL1 Kinase 100%
• Secondary Fusion 100%
• Drug Sensitivity 25%
• Validation Studies 25%
• RNA Sequencing (RNA-seq) 25%
• Tyrosine Kinase Inhibitor 25%
• Drug Resistance 25%
• BCR-ABL Fusion Gene 25%
• Fusion Gene 25%
• Proliferation Rate 25%
• Drug Screening 25%
• Combined Therapy 25%
• Rate Sensitivity 25%
• Runt-related Transcription Factor 1 (RUNX1) 25%
• Gene Expression Analysis 25%
• ABL1 25%
• Cell Line Models 25%
• MECOM 25%

Medicine and Dentistry

• Phosphotransferase 100%
• Chronic Myelogenous Leukemia 100%
• Fusion Protein 100%
• In Vitro 50%
• Gene Expression Profiling 50%
• RNA Sequence 50%
• Tyrosine-Kinase Inhibitor 50%
• Drug Screening 50%
• Drug Resistance 50%
• Drug Sensitivity 50%
• Combined Therapy 50%
• Fusion Gene 50%
• Cell Line Study 50%
• MDS1 and EVI1 Complex Locus Protein 50%

Biochemistry, Genetics and Molecular Biology

• Phosphotransferase 100%
• Kinase 100%
• Fusion Protein 100%
• Myeloid 100%
• Gene Expression Profiling 50%
• RNA Sequence 50%
• Drug Resistance 50%
• Drug Sensitivity 50%
• Fusion Gene 50%
• Drug Screening 50%
• Tyrosine Kinase Inhibitor 50%
• RUNX1 50%
• MDS1 and EVI1 Complex Locus Protein 50%